Development of Anal Cancer Treatment selection model by Organoids (ACTOR)
- Conditions
- anal canceranal carcinoma10017991
- Registration Number
- NL-OMON56888
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 60
Inclusion Criteria
In order to be eligible to participate in this study, a subject must meet all
of the following criteria:
1. Patients with anal SCC who will start treatment with chemoradiotherapy,
including:
Mitomycin C + Capecitabine + radiotherapy; or patients with metastatic anal SCC
who will start treatment with either chemotherapy (e.g. carboplatin/paclitaxel)
or immunotherapy.
2. Patient*s age older than 18 years, willing and able to comply with the
protocol as judged by the investigator with a signed informed consent.
Exclusion Criteria
1. Safely obtain biopsy: If a biopsy cannot be safely obtained as determined by
either the surgeon or the radiologist and/or the treating physician, the
patient will be excluded from the study.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method